Elevated levels of FGL-1 in cancer may contribute to suppression of activated T cells and evasion of antitumor immunity,8 however, relative contributions of disrupting LAG-3 interactions with FGL-1 or MHC-II in patients is unclear. The gene discussed is FGL1; the disease is cancer.